Ablynx receives Euro 1.1m grant to develop administration routes for nanobodies

Published: 24-Nov-2009

Belgian biopharmaceutical company Ablynx has been awarded a grant worth Euro 1.1m by the Flemish agency for Innovation by Science and Technology (IWT) to accelerate its development of alternative routes of administration for therapeutic nanobodies.


Belgian biopharmaceutical company Ablynx has been awarded a grant worth Euro 1.1m by the Flemish agency for Innovation by Science and Technology (IWT) to accelerate its development of alternative routes of administration for therapeutic nanobodies.

In December 2008, Ablynx concluded its first feasibility study of pulmonary delivery and demonstrated in vivo that anti-viral nanobodies protect against viral infection and eliminate active virus when delivered via an intra-pulmonary route.

The company has also demonstrated that nanobody administration via the lungs results in up to 10 times longer systemic exposure compared with intravenous administration.

Ablynx will use the grant to accelerate the development of pulmonary and oral delivery technologies for its nanobodies. In addition, it will continue to explore several other potential routes including topical and ocular administration.

You may also like